Today, Professor Charlotte Cordonnier explains her involvement in the National PreciDIAB Center as a neurologist working on the prevention of comorbidities in diabetic patients.
Pr. Charlotte Cordonnier
Pr. Charlotte Cordonnier
Neurologist at Lille University Hospital and researcher at Inserm.
Why, as a neurologist, did you choose to get involved in the Center National PreciDIAB?
I am a neurologist and I treat stroke patients. Among the patients we treat urgently, a third of them are diabetics; therefore their prognosis is more severe. However, even today, the management of diabetic patients is the same as for those who do not. However, it is probable that certain diseases, and in particular in my specialty, the cerebrovascular disease is different in these diabetic people. Customizing care based on patient characteristics is one of the key elements in improving our medical practices.
What are the projects that you are going to carry out within the National Center, and what are their objectives?
Diabetes affects the brain, nerves, heart, kidneys, eyes, and many other organs. Initially, we bring together in PreciDIAB doctors specializing in all these complications. It is rare to have such a multidisciplinary approach, and this is one of the major strengths of the National Center. Understanding what leads to complications related to diabetes will then allow us to develop strategies for the prevention and protection of these very important organs, the brain and the heart.
What are the ambitions in terms of expected results? How will these perspectives change the understanding or the way we manage metabolic diseases and diabetes in particular?
We will first create cohorts of diabetic patients. We will explore finely and in a non-invasive way, the functioning of their brains and their hearts by comparing them to non-diabetic patients. For example, the exploration of the brain will consist of an assessment of cognitive functions (visual or verbal memory, language, writing, reading, arithmetic, attention, etc.). An evaluation of the morphology of the brain will be done by a brain MRI and its functioning by a functional MRI. These observations will, in the long term, make it possible to identify the factors favoring complications of the brain (stroke or memory disorders). Thus, we can then move on to the second step, which will be to evaluate in a clinical study new prevention strategies specific to diabetic patients.
Promoting this multidisciplinary and preventive clinical approach within PreciDIAB is an exciting adventure.
Discover the interviews...
Professor of medical pharmacology Director of the Clinical Investigation Center (CIC 1403 Inserm-CHU de Lille) and of the Clinical Trial Unit dedicated to diabetes.
Physiology & Cardiovascular Functional Explorations CHU Lille, Inserm U1011
Research director at Inserm, scientific manager of the center’s diabetes genomic medicine programs, head of EquipEx LIGAN-PM and team leader at UMR 1283/8199
PhD, e-One Health professor and director of the Multi-Omics Statistics Department at the University of Surrey, associate researcher at the University of Lille, and in charge of the “studies of links between diabetes and cancer risks” project within the Center National PreciDIAB
Department of Endocrinology Diabetology, Nutrition Metabolisms of the University Hospital of Lille.
Research Engineer in Bioinformatics, responsible for the bioinformatics platform of UMR 1283/8199
Professor of biochemistry and researcher at UMR 1011 Nuclear Receptors, Cardiovascular Diseases and Diabetes.
Nutritionist, specialist in endocrinology and metabolic diseases, and head of the Nutrition & Physical Activity Department at the Institut Pasteur de Lille (IPL).
University professor – Hospital practitioner in the acute geriatric medicine department, specialist in the course of care, drug interactions and artificial intelligence.
Previous
Next
